Cordlife’s 52% Revenue Surge Masks Deep Crisis: 5 Surprising Takeaways from Its Latest Report

Introduction

On the surface, Cordlife Group’s latest financial results for the first nine months of 2025 (9M2025) look surprisingly robust. The company reported a 52.2% year-on-year revenue increase to S29.4 million and managed to slash its net loss by 49.1% to S7.1 million. For a company mired in a public crisis, these numbers seem to defy gravity.

But how does a company facing intense regulatory scrutiny and a crisis of trust post such encouraging figures? A deeper dive into Cordlife’s financial disclosures reveals a far more complex and troubling reality. This article explores five surprising takeaways that peel back the layers of the headline numbers to show what’s really happening inside the embattled cord blood bank.

——————————————————————————–

1. The 52% Revenue Growth Is an Illusion

The most counter-intuitive finding is the story behind the impressive revenue growth. The massive 52.2% jump in revenue is not the result of a booming business; it is primarily due to an accounting anomaly from the previous year.

In the nine-month period of 2024, Cordlife had to make a massive revenue reversal of approximately S9.7 million, largely due to provisions for refunds related to its storage tank failures. In contrast, the reversal for the same period in 2025 was a much smaller S0.2 million.

When these significant reversals are excluded to get a clearer picture of underlying performance, the story changes dramatically. On a like-for-like basis, revenue only grew by a modest 2.1%, from S29.0 million in 9M2024 to S29.6 million in 9M2025. This context is crucial for understanding that the company’s actual performance is far from the explosive growth the headline number suggests.

2. The Regulatory Nightmare Is Far From Over

Cordlife’s engagement with Singapore’s Ministry of Health (MOH) can only be described as a regulatory rollercoaster. Cordlife’s relief was tragically brief. After a grueling year of remediation following its initial suspension in late 2023, the company began a controlled resumption of services from 15 September 2024 and celebrated a full resumption of its Singapore operations on January 14, 2025.

But just over eight months later, on September 29, the axe fell again. Regulators, citing new non-compliance issues found during inspections in July, issued an “Intended Suspension” for a full year, plunging the company straight back into crisis. The failures were not minor; they related to a broad spectrum of core processes, from quality management and supplier management to incident reporting and risk assessment. In response, Cordlife voluntarily stopped collecting new cord blood units in Singapore from September 30, 2025, demonstrating that its compliance issues are deep-seated and unresolved.

3. The “Low-Risk” Tanks Weren’t So Low-Risk After All

At the heart of Cordlife’s crisis are the cryogenic storage tanks that were exposed to temperature irregularities. While the company previously identified and dealt with “high-risk” tanks, further testing on five tanks initially deemed “low-risk” has delivered another shocking blow.

The results from the “Additional Low-Risk Tanks Test” revealed that while samples from two of the five tanks passed, samples from the other three failed to meet the required criteria for viability and potency. More alarmingly, the MOH noted that Cordlife’s “root cause analysis could not identify conclusive reasons for what could have caused the tested samples in the Remaining 3 Low-Risk Tanks to fail.” This admission is more damaging than the failure itself. It signals a fundamental breakdown in quality control and investigative capability, leaving customers to wonder: if the company doesn’t know why this happened, how can it possibly guarantee it won’t happen again?

4. The Company Is Bleeding, But Has a S$62.6 Million Cash Cushion

Despite the operational chaos, mounting customer claims, and ongoing regulatory battles, Cordlife surprisingly maintains a strong balance sheet. As of September 30, 2025, the Group has a “healthy net cash position” of S$62.6 million in cash, fixed deposits, and short-term investments.

This financial strength is juxtaposed against immense and unquantified risks. The company’s own “Going Concern Assessment” highlights several high-stakes threats to this cash pile, including:

• Potential refunds for the newly failed “low-risk” tanks.
• Claims from customers alleging damage to their cord blood units.
• Potential fines and penalties from regulators.

While the cash provides a critical buffer for survival, it is under significant pressure from multiple unresolved issues. The company has the funds to fight, but the potential costs are still a major unknown.

5. The CEO Is Focused on a Turnaround, Not Growth

The public statement from Cordlife’s Group CEO, Ms Chen Xiaoling, offers a clear window into the company’s current mindset. Her focus is not on expansion or new initiatives but on fundamental survival and repair.

“Moving forward, our priority is to stabilize operations, preserve capital, and reposition the business for recovery. We believe in the underlying value of our network, our overseas hubs and the strong fundamentals of the cord blood banking business. Our focus remains on driving a sustainable turnaround for the benefit of all stakeholders.”

This is the language of a company in crisis mode. Her focus on “preserving capital” isn’t just corporate jargon; it’s a direct response to the unquantified liabilities from failing tanks and potential regulatory fines that threaten the S$62.6 million cash cushion. Her call to “stabilize operations” is a stark admission that the company is still failing at the fundamental compliance tasks that led to the new “Intended Suspension” notice from regulators. It is an implicit acknowledgment of the gravity of the situation and the long, difficult road ahead to rebuild not just its operations, but its reputation.

——————————————————————————–

Conclusion

Cordlife’s 9M2025 financial report presents a stark contrast between its headline figures and the deep-seated operational and regulatory turmoil it faces. The seemingly positive revenue growth is an accounting mirage, while new revelations about its storage tanks and a fresh suspension notice from regulators show the crisis is deepening.

The company’s future depends less on its financial reports and more on its ability to fundamentally resolve its profound quality control and compliance issues. With significant cash on hand, Cordlife has the resources to weather the storm, but the ultimate question remains: can it ever regain the one asset that’s truly priceless—its customers’ trust?

WATCH THE EXPLAINER VIDEO BELOW:

LISTEN TO THE PODCAST BELOW:

Related stories: Why Livingstone Health’s Revenue Is Up But Profits Are Down In HY2026